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Abstract 
Background: Half of the adults with current asthma among the US National Health and Nutrition Examination 
Survey (NHANES) participants could be classified in more than one hypothesis-driven phenotype. A data-driven 
approach applied to the same subjects may allow a more useful classification compared to the hypothesis-driven 
one.
Aim: To compare previously defined hypothesis-driven with newly derived data-driven asthma phenotypes, identi-
fied by latent class analysis (LCA), in adults with current asthma from NHANES 2007–2012.
Methods: Adults (≥ 18 years) with current asthma from the NHANES were included (n = 1059). LCA included vari-
ables commonly used to subdivide asthma. LCA models were derived independently according to age groups: < 40 
and ≥ 40 years old.
Results: Two data-driven phenotypes were identified among adults with current asthma, for both age groups. The 
proportions of the hypothesis-driven phenotypes were similar among the two data-driven phenotypes (p > 0.05). 
Class A < 40 years (n = 285; 75%) and Class A ≥ 40 years (n = 462; 73%), respectively, were characterized by a predomi-
nance of highly symptomatic asthma subjects with poor lung function, compared to Class B < 40 years (n = 94; 25%) 
and Class B ≥ 40 years (n = 170; 27%). Inflammatory biomarkers, smoking status, presence of obesity and hay fever did 
not markedly differ between the phenotypes.
Conclusion: Both data- and hypothesis-driven approaches using clinical and physiological variables commonly 
used to characterize asthma are suboptimal to identify asthma phenotypes among adults from the general popula-
tion. Further studies based on more comprehensive disease features are required to identify asthma phenotypes in 
population-based studies.
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Introduction
Airways diseases, such as asthma and chronic obstructive 
pulmonary disease (COPD), comprise a heterogeneous 
set of subtypes with different underlying pathophysi-
ological mechanisms [1–3]. Both hypothesis-driven and 
data-driven methods can be used to classify patients into 
sub-groups of airways diseases [4–6].
The hypothesis-driven approach classifies airways 
diseases based on pre-defined criteria following immu-
nopathology concepts and asthma literature, while in 
data-driven methods no prior disease classification is 
required [7, 8]. Data-driven approaches have provided 
insights into “novel” phenotypes of complex disease 
pathogenesis, suggesting disease stratification depending 
on the individual pathophysiologic characteristics [8–11].
Most studies on asthma phenotyping using data-driven 
methods emphasize patients with moderate to severe 
asthma and/or clinically-based settings [12–15]. There-
fore, the generalization to the general asthma population 
may be limited.
Different types of data-driven methods have been 
widely used in airway diseases, such as hierarchical [12], 
partitioning [14], and latent class analysis (LCA) [10]. 
Notably, LCA appeared to account better for the hetero-
geneity of airways symptoms, compared to other com-
monly used data-driven approaches (e.g. partitioning 
around medoids) [16]. Moreover, the application of the 
latent class assignments developed from a national data 
source has previously demonstrated higher degrees of 
generalizability [17].
Recently, we reported a significant overlap between five 
distinct hypothesis-driven asthma phenotypes in adults 
from the general population included in the US National 
Health and Nutrition Examination Survey (NHANES) 
[18]. We have emphasized that a combination of clinical 
information and biomarkers, using a more comprehen-
sive data analysis approach, such as data-driven methods, 
could provide a better taxonomy of non-severe asthma.
In this study, we aimed to compare previously defined 
hypothesis-driven asthma phenotypes [18] with data-
driven asthma phenotypes derived by applying LCA 
to a sample of adults representative of the US general 
population.
Methods
Study setting and participants
We have included subjects that participated in the 
NHANES study, a nationally representative survey of 
the civilian, non-institutionalized US population per-
formed with the aim of gathering data regarding health 
and nutritional status. Protocols were approved by the 
National Center for Health Statistics Research Ethics 
Review Board and all participants gave written informed 
consent. Detailed information can be found in the 
NHANES documentation (www.cdc.gov/nchs/nhane 
s.htm).
Data from three NHANES surveys was used 
(n = 30,442). We included adults (≥ 18  years old) with 
current asthma (n = 1059), defined by a positive answer 
to the questions [18]: “Has a doctor ever told you that you 
have asthma?” together with “Do you still have asthma?”, 
and either “wheezing/whistling in the chest in the past 
12 months” or “asthma attack in the past 12 months.”
Variables
Anthropometric and demographic characteristics, 
such as age, gender, body mass index (BMI), and smok-
ing status were analysed, as well as blood eosinophils 
(B-Eos) count, fraction of exhaled nitric oxide (FeNO) 
and spirometric parameters. FeNO and spirometry were 
performed following ATS/ERS recommendations [19, 
20]. Basal predicted values of forced expiratory volume 
during the first second  (FEV1) and forced vital capacity 
(FVC) were calculated [21, 22] and abnormal values were 
defined as being below the lower limit of normal (LLN) 
[23].
Hypothesis‑driven asthma phenotypes
The analysis based on the report of smoking status, pres-
ence of obesity and inflammatory markers enabled the 
definition of five asthma phenotypes [18]: B-Eos-high 
asthma phenotype, if B-Eos ≥ 300/mm3; FeNO-high 
asthma, if FeNO ≥ 35  ppb; B-Eos&FeNO-low asthma, 
if B-Eos < 150/mm3 and FeNO < 20  ppb; asthma with 
obesity (AwObesity), if BMI ≥ 30  kg/m2; and asthma 
with concurrent COPD (AwCOPD), if subjects had 
self-reported chronic bronchitis/emphysema with age 
of diagnosis ≥ 40 years and being either a current or an 
ex-smoker (ever smoked). Subjects were considered as 
“non-classified” if they did not meet the criteria for any of 
the defined asthma phenotypes. Additionally, to account 
for individuals with probable co-existence of asthma and 
COPD and minimize age as a confounding variable, we 
conducted the analysis considering two age groups: < 40 
and ≥ 40 years old [18].
Data‑driven asthma phenotypes
LCA was used to identify asthma phenotypes in an unsu-
pervised manner (data-driven approach). Two models 
for “current asthma” were developed (Additional file  1: 
Table  S1): Model 1 was based on the 4 variables previ-
ously used to define the hypothesis-driven asthma 
phenotypes (BMI ≥ 30  kg/m2, ever-smoking status, 
FeNO ≥ 35  ppb, B-Eos ≥ 300/mm3) [18]; and in Model 
2, we have added to the former 4 variables, sex, early 
asthma onset (< 16 years old), wheezing-related questions 
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(presence/absence of at least one wheezing attack, 
wheezing with exercise, sleep disturbance by wheezing, 
limit activity by wheezing, absenteeism by wheezing), 
asthma-related emergency department (ED) visit in the 
previous 12  months,  FEV1/FVC < LLN,  FEV1 < LLN, and 
self-reported hay fever.
Additionally, to explore the results in different “asthma 
populations”, we’ve developed two other models using 
similar variables. For the “ever asthma” subgroup (model 
3) we included subjects with a positive answer to “Has a 
doctor ever told you that you have asthma?” (n = 2611); 
and for the “difficult asthma” (model 4) we included 
subjects with poor asthma-related outcomes, defined 
as current asthma plus, at least, one of the following: 
asthma-related ED visit,  FEV1 < LLN, or oral corticoster-
oids use in the past 30 days (n = 673) (Additional file 1: 
Table S1).
Latent class models were derived independently for 
each age group, using the same variables, and a second-
ary analysis without stratifying by age was done on the 
three asthma subgroups. The most appropriate number 
of clusters was determined by examining commonly used 
criteria [24]. Further methodological details are found in 
the Additional file 1.
Statistical analysis
All analyses considered the complex multistage sampling 
and 6-year sampling weights provided by the NHANES 
documentation [25]. LCA was performed with MPlus 
(version 6.12), that considered the complex survey design 
of NHANES when performing LCA-modelling. All other 
analysis was performed in Stata/IC 15.1 (Stata Corp, Col-
lege Station, TX, USA). A p-value < 0.05 was considered 
statistically significant.
Results
We included 1059 adults with current asthma. The 
weighted proportions of the previously defined hypoth-
esis-driven asthma phenotypes, according to age groups 
(< 40 and ≥ 40 years old) were, respectively: 42% and 53% 
with AwObesity; 34% and 37% with B-Eos-high asthma; 
26% and 21% for B-Eos&FeNO-low; 18% and 19% with 
FeNO-high asthma; and 19% AwCOPD, in the older 
group [18]. In addition, 17% and 12% of the individuals 
in the < 40 and ≥ 40 years old groups, respectively, were 
categorized as “non-classified”.
In Model 1, LCA was not able to differentiate any 
asthma subgroup among subjects with current asthma 
(Additional file 1: Table S1). On the other hand, by add-
ing more asthma-related variables (Model 2), LCA iden-
tified a two-class model as the best solution for both 
age groups (Table 1, Additional file 1: Table S1). Classes 
A < 40  years (n = 290; 75%) and A ≥ 40  years (n = 494; 
73%) had marked predominance of highly symptomatic 
asthma subjects, with poorer lung function, compared 
to classes B < 40  years (n = 96; 25%) and B ≥ 40  years 
(n = 179; 27%), respectively (Table 1). Regarding inflam-
matory markers, the proportion of patients with high 
levels of B-Eos and FeNO was not significantly different 
between classes, both in the younger group (p = 0.99 and 
p = 0.82, respectively) and in the older group (p = 0.57 
and p = 0.53).
Figure 1 shows that the distribution of the hypothesis-
driven phenotypes is similar (p > 0.05) in both classes 
identified by LCA regardless age group.
Additionally, LCA identified 2 classes on the models for 
“ever-asthma” and “current asthma” without stratifying 
by age, but not for the difficult-asthma sub analysis where 
no subgroup was identified (Additional file 1: Table S1).
Discussion
This was the first study comparing previously defined 
hypothesis-driven asthma phenotypes with data-driven 
ones in a sample representative of the US general popu-
lation. The proportions of the hypothesis-driven phe-
notypes were similar between the two data-driven 
phenotypes obtained by LCA using clinical and physio-
logical variables commonly used to characterize asthma.
Previous studies using data-driven approaches contrib-
uted to the definition of clusters/phenotypes based on 
similarities in clinical and inflammatory biomarkers [9, 
12–14]. However, these approaches have been scarcely 
applied to adults with asthma from population-based 
studies. The studies from Siroux et al. [26] and Mäkikyrö 
et al. [27] provided further evidence for identifying sub-
groups of asthma based on clinical markers and ques-
tionnaire data commonly available in primary health care 
or large epidemiological studies and found a larger range 
of asthma phenotypes.
Our study showed that performing LCA with the 
variables used to define some of the most common 
hypothesis-driven asthma phenotypes, could not iden-
tify subgroups within adults with current asthma from 
the general population. By including additional clinical 
and physiological variables commonly used to classify 
asthma, LCA identified two data-driven phenotypes in 
the same subjects. Overall, these phenotypes only dif-
fered in symptom frequency and lung function param-
eters. Inflammatory biomarkers, presence of obesity, 
smoking status, age of asthma onset and self-reported 
hay fever were not different between classes.
Moreover, using a less stringent asthma definition (ever 
asthma) and in subjects with poor clinical outcomes (dif-
ficult asthma), these variables were also suboptimal to 
differentiate asthma subgroups.
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In contrast to studies with severe asthma patients, 
our results suggest that, for the general asthma popula-
tion, the clinical and physiological variables available to 
classify asthma and commonly used predefined cut-offs 
seem to be insufficient to identify specific phenotypes. 
The inclusion in data-driven models of additional easily 
measurable biomarkers that have already been shown to 
be helpful in discriminating asthma phenotypes in this 
population (e.g. serum IgE and/or periostin) [28, 29], 
combined with comprehensive clinical, physiologic, and/
or disease features, might result in the identification of 
more precise phenotypes. Also, the identification of new, 
more accurate biomarkers could also improve phenotyp-
ing [30]. Furthermore, the use of fixed cut-offs values, 
although common and more intuitive for daily clinical 
practice, may potentially miss more complex, and yet 
unidentified phenotypes. The use of absolute values (as 
seen in other studies [13, 31, 32]), or appropriate refer-
ence equations for predicted values [33, 34] could be 
more adequate.
Similarly, research efforts are being made to integrate 
clinical characteristics with available biomarkers to iden-
tify data-driven asthma phenotypes in children [35, 36]. 
However, the obtained phenotypes vary on key features 
that are more pronounced during childhood, including 
natural history of wheeze over time [37], suggesting that 
further work is required to compare data- and hypothe-
sis-driven approaches to identify asthma phenotypes in 
children.
Limitations inherent to a survey study design must be 
acknowledged and the self-reported variables may lead 
to misclassifications and information biases; to account 
for these biases, we used previously validated definitions 
[38, 39]. Also, despite including the most commonly used 
variables for respiratory disease assessment available in 
the NHANES study, when using the less stringent asthma 
definition, the differentiation of asthma subgroups was 
not improved in this population. However, to reduce the 
risk of poor LCA-class differentiation, we did not include 
any of the variables used in the asthma groups defini-
tion into the LCA models. Finally, LCA modelling should 
comprehend all the domains relevant to the understand-
ing of the disease to classify observations into discrete 
and mutually exclusive classes [40], suggesting that the 
use of predefined cut-offs and the lack of data regard-
ing, for example, objective assessment of atopy, nasal and 
ocular symptoms (which have proved to be useful in the 
stratification of allergic respiratory diseases [10, 41]), may 
have limited the ability to differentiate specific asthma 
phenotypes using unsupervised analysis.
Table 1 Proportions of each variable according to the LCA-classes identified in Model 2 (subjects with current asthma, 
n = 1059)
FEV1 forced expiratory volume in the first second, FVC forced vital capacity, LLN lower limit of normality, ED emergency department, FeNO fractional exhaled nitric 
oxide, B-Eos blood eosinophils count, BMI body mass index
Variables are ordered by the highest mean difference between the 2 classes of each age group and each coloured box represents the prevalence of the variables 
within the class, ranging from 0% (light yellow) to 100% (red)
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In conclusion, this brief communication extends our 
previous work on the need for a broader data analysis 
combining different asthma-related domains for differ-
entiating phenotypes in the general asthma population 
[18]. The clinical and physiological variables commonly 
used to subdivide asthma seem to be insufficient to dif-
ferentiate specific asthma phenotypes among adults from 
the general population, irrespective of using data-driven 
or hypothesis-driven approaches. Further studies based 
on more comprehensive disease features are required to 
identify asthma phenotypes with the potential to be use-
ful for clinicians and for population-based research.
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